Compare UGRO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UGRO | SNGX |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.2M |
| IPO Year | 2018 | 2006 |
| Metric | UGRO | SNGX |
|---|---|---|
| Price | $19.23 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 10.3M | 170.8K |
| Earning Date | 02-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,008,850.00 | $119,371.00 |
| Revenue This Year | $98.41 | N/A |
| Revenue Next Year | $23.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $1.00 |
| 52 Week High | $39.68 | $6.23 |
| Indicator | UGRO | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.93 | 44.38 |
| Support Level | $0.71 | $1.01 |
| Resistance Level | $39.68 | $1.47 |
| Average True Range (ATR) | 6.81 | 0.09 |
| MACD | 1.28 | -0.01 |
| Stochastic Oscillator | 44.90 | 43.75 |
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).